ALGS
Companies
NASDAQ
Aligos Therapeutics, Inc.
Health Care
$7.26
-$32.58 (-81.78%)
Price Chart
Overview
About ALGS
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Market Cap
$42.2M
Volume
1.1M
Avg. Volume
1.2M
P/E Ratio
-0.4161074
Dividend Yield
0.00%
Employees
75.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.89
Moderate Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ALGS shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$42.2M
Volume1.1M
P/E Ratio-0.42
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 10, 2025Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025